Neuro-oncology

EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS.

Neuro-oncology

Brice Tiret, Adam Autry, Ilwoo Park, Ming Lu, Rana Anjum, Liza Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, James Rubenstein, Myriam M Chaumeil

IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES.

Neuro-oncology

Diego Carrera,Josie Hayes,Soeren Mueller,Samuel J Shelton,Toni Weinschenk,Colette Song,Jens Fritsche,Oliver Schoor,Sabrina Kuttruff-Coqui,Norbert Hilf,Gary Kohanbash,Payal Watchmaker,Michael C Oldham,Joseph Costello,Harpreet Singh,Hideho Okada

GENE-33. THE 3D EVOLUTION AND IN VIVO GROWTH PATTERNS OF GLIOMA CELL POPULATIONS.

Neuro-oncology

Stephanie Hilz,Samuel J Shelton,Llewellyn Jalbert,Hang K Wong,Tali Mazor,Chibo Hong,Josie Hayes,Tracy Luks,Henrik Bengtsson,Annette Molinaro,Michael McDermott,Mitchel S Berger,Daniel Lim,Aaron Diaz,Joanna J Phillips,Susan Chang,Sarah Nelson,Michael C Oldham,Joseph Costello

PATH-07. FAMILIAL MELANOMA-ASTROCYTOMA SYNDROME: SYNCHRONOUS DIFFUSE ASTROCYTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA IN A PATIENT WITH GERMLINE CDKN2A/B DELETION AND A SIGNIFICANT FAMILY HISTORY.

Neuro-oncology

Winward Choy,Andrew K Chan,Seunggu J Han,Daniah Beleford,Manish K Aghi,Mitchel S Berger,Joseph T Shieh,Andrew W Bollen,Arie Perry,Joanna J Phillips,Nicholas Butowski,David A Solomon

GENE-06. EXPRESSION OF LINC00152, A PUTATIVE SPONGE FOR TUMOR-SUPPRESSIVE micro-RNA, CORRELATES WITH GLIOMA GRADE.

Neuro-oncology

Soeren Mueller,Daniel He,Josie Hayes,Siyuan Liu,Martina Malatesta,Arnold Kriegstein,Manish Aghi,Daniel Lim,Aaron Diaz

Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Neuro-oncology

Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Neuro-oncology

Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Neuro-oncology

Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.

Neuro-oncology

Mitchell LA, Lopez Espinoza F, Mendoza D, Kato Y, Inagaki A, Hiraoka K, Kasahara N, Gruber HE, Jolly DJ, Robbins JM

Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.

Neuro-oncology

Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, Takahashi M, Matsumoto H, Hacke K, Kruse CA, Ostertag D, Robbins JM, Gruber HE, Jolly DJ, Kasahara N

Pages